Affiliation:
1. Linkou Chang Gung Memorial Hospital
Abstract
Abstract
Background:
Immune checkpoint inhibitors (ICI) are promising treatment options for various cancers. However, their use is associated with immune-related adverse events (irAEs), including ICI-induced diabetes mellitus (ICI-DM). This study aimed to investigate the clinical features of ICI-DM, with a particular focus on alterations to pancreatic volume.
Methods:
We conducted a retrospective review of 2829 patients who received ICI treatment at the Chang Gung Memorial Hospital, Linkou, between January 2014 and December 2021. New-onset diabetes or diabetic ketoacidosis (DKA) was identified in ten patients receiving ICI therapy. Pancreatic volumes were assessed by manual segmentation of computed tomography (CT) images before and after ICI-DM diagnosis.
Results:
Among these ten patients, nivolumab was the most commonly used ICI (50.0%), followed by pembrolizumab (30.0%) and atezolizumab (20.0%). One patient received combination therapy with nivolumab and ipilimumab. The median age was 63.01 years (range: 40.1 − 87.8). ICI-DM developed after a median of 13.5 cycles (range: 2 − 42) of ICI treatment or 9.85 months (range:1.5 − 21.3) since ICI initiation. The initial presentation was DKA in 60.0% of patients. All patients had low or undetectable C-peptide levels (range: <0.033 − 0.133 nmol/L) and were negative for most type 1 diabetes mellitus (T1DM)-related autoantibodies; only one patient tested positive for glutamic acid decarboxylase antibodies. CT imaging revealed significant pancreatic atrophy, with a median pancreatic volume decrease of 19.92% (P = 0.038) from baseline and sustained significant decline at last follow-up (median − 37.14%, P = 0.012).
Conclusions:
ICI-DM is often accompanied by pancreatic atrophy and approximately two-thirds of patients initially present with DKA. Although most patients with ICI-DM do not have T1DM-related autoantibodies, awareness of decreased pancreatic volumes with CT imaging is valuable for predicting diabetic emergencies in patients treated with ICIs.
Trial registration:
This study was approved by the Institutional Review Board of the Chang Gung Memorial Hospital (No.202201766B0).
Publisher
Research Square Platform LLC
Reference45 articles.
1. Reporting of Immune Checkpoint Inhibitor Therapy–Associated Diabetes, 2015–2019;Liu J;Diabetes Care,2020
2. Clinical development of targeted and immune based anti-cancer therapies;Seebacher NA;J Exp Clin Cancer Res,2019
3. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade;Postow MA;N Engl J Med,2018
4. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy;Hofmann L;Eur J Cancer,2016
5. Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes;Wright JJ;Diabetes Care,2018